SCHEMBL15411656

SCHEMBL15411656

Cc1c(-c2ccnn2-c2ccc(C#N)cc2)cn2nc(NC(=O)NCCCN(C)CCCN(C)C)nc2c1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ELANE P08246 5/20 0.42
EPHX2 P34913 3/20 0.35
PTGS2 P35354 3/20 0.35
BRAF P15056 5/20 0.34
ITGB2 P05107 1/20 0.34
ICAM1 P05362 1/20 0.34
ITGAL P20701 1/20 0.34
RAD52 P43351 3/20 0.33
PAX8 Q06710 2/20 0.33
MALT1 Q9UDY8 1/20 0.32
ADORA2A P29274 1/20 0.32
CTSK P43235 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15411653 0.98 ELANE (0.43) ELANEEPHX2PTGS2BRAFITGB2
SCHEMBL15411892 0.91 ELANE (0.44) ELANEBRAFRAD52PAX8MALT1
SCHEMBL15411853 0.91 ELANE (0.44) ELANEEPHX2PTGS2BRAFITGB2
SCHEMBL15410928 0.91 ELANE (0.45) ELANEEPHX2PTGS2ITGB2ICAM1
SCHEMBL15411002 0.91 ELANE (0.40) ELANEBRAFRAD52CTSK
SCHEMBL15425453 0.90 ELANE (0.43) ELANEEPHX2PTGS2ITGB2ICAM1
SCHEMBL15412357 0.90 ELANE (0.44) ELANEBRAFMALT1ADORA2ACTSK
SCHEMBL15411663 0.89 ELANE (0.42) ELANEBRAFRAD52CTSK
SCHEMBL15412108 0.89 ELANE (0.46) ELANEEPHX2PTGS2BRAFMALT1
SCHEMBL18043801 0.89 ELANE (0.42) ELANEBRAFADORA2ACTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2872509-B1 INHIBITION OF ENZYMES CHIESI FARMA SPA (IT) 2016-09-14 EP disclosed
EP-2872509-B1 INHIBITION OF ENZYMES CHIESI FARMA SPA (IT) 2016-09-14 EP disclosed
US-9199984-B2 Inhibition of enzymes CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-01 US disclosed
US-9199984-B2 Inhibition of enzymes CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-01 US disclosed
US-9199984-B2 Inhibition of enzymes CHIESI FARMACEUTICI S.P.A. (IT) 2015-12-01 US disclosed
EP-2872509-A1 INHIBITION OF ENZYMES Chiesi Farmaceutici S.p.A. (IT) 2015-05-20 EP disclosed
US-20140018345-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A (IT) 2014-01-16 US disclosed
WO-2014009425-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A. (IT) 2014-01-16 WO disclosed
US-20140018345-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A (IT) 2014-01-16 US disclosed
US-20140018345-A1 INHIBITION OF ENZYMES CHIESI FARMACEUTICI S.P.A (IT) 2014-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018345-A1 INHIBITION OF ENZYMES SERPINB1, ELANE, MPO ELANE 2/4885EPHX2 473/4885PTGS2 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.